Literature DB >> 16262755

In-vitro evaluation of the PALL Leukotrap Affinity Prion Reduction Filter as a secondary device following primary leucoreduction.

C Saunders1, P Herbert, G Rowe, M Hayward, K Wilkins, J Milligan, M Stenning, A Seacombe, C Prowse.   

Abstract

BACKGROUND AND OBJECTIVES: A filter (PRF1) designed to remove abnormal prion proteins from red-cell units has been developed. The purpose of this study was to evaluate the quality of red cells produced using this device.
MATERIALS AND METHODS: Leucocyte-depleted red-cell units (CPD, CPD-A1 and CPD/SAGM) processed according to standard UK practices were filtered using PRF1. Filtered and control units were stored and sampled on day 1, day 7 and on the date of expiry and were tested using standard measures of red-cell quality.
RESULTS: Filtered units were found to have significantly higher percentage haemolysis levels, lower haemoglobin levels and a smaller volume compared with controls. All results, however, were well within the permitted 0.8% haemolysis level at the end of storage and all units met the UK guidelines for haemoglobin and volume. The other test parameters measured showed no significant differences between the test and control units.
CONCLUSIONS: The PRF1 filter was found to be easy to use and resulted in red-cell units that met all relevant UK and European Guidelines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16262755     DOI: 10.1111/j.1423-0410.2005.00703.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

1.  LeukoCatch, a quick and efficient tool for the preparation of leukocyte extracts from blood.

Authors:  Daisuke Okuzaki; Shoichi Kimura; Norikazu Yabuta; Toshinari Ohmine; Hiroshi Nojima
Journal:  BMC Clin Pathol       Date:  2011-08-17

2.  Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission.

Authors:  Caroline Lacroux; Daisy Bougard; Claire Litaise; Hugh Simmons; Fabien Corbiere; Dominique Dernis; René Tardivel; Nathalie Morel; Stephanie Simon; Séverine Lugan; Pierrette Costes; Jean Louis Weisbecker; François Schelcher; Jacques Grassi; Joliette Coste; Olivier Andréoletti
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.